DPHARMA Stock Overview
An investment holding company, researches, develops, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Duopharma Biotech Berhad Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | RM 1.23 |
| 52 Week High | RM 1.45 |
| 52 Week Low | RM 1.10 |
| Beta | 0.70 |
| 1 Month Change | -1.60% |
| 3 Month Change | -7.52% |
| 1 Year Change | -0.81% |
| 3 Year Change | -18.54% |
| 5 Year Change | -2.96% |
| Change since IPO | 205.03% |
Recent News & Updates
Recent updates
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005
Aug 27
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018
Apr 04Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price
Feb 17These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively
Oct 21Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005
Aug 18Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)
Aug 07Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year
Mar 28Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)
Mar 27We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings
Nov 26Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021
Nov 25Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005
Aug 20Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly
May 22Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend
Apr 13A Look At The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)
Mar 14Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly
Feb 12Do Institutions Own Duopharma Biotech Berhad (KLSE:DPHARMA) Shares?
Jan 28
Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?
Jan 12Shareholder Returns
| DPHARMA | MY Pharmaceuticals | MY Market | |
|---|---|---|---|
| 7D | 0% | -0.8% | -0.7% |
| 1Y | -0.8% | -5.6% | 6.1% |
Return vs Industry: DPHARMA exceeded the MY Pharmaceuticals industry which returned -5.6% over the past year.
Return vs Market: DPHARMA underperformed the MY Market which returned 6.1% over the past year.
Price Volatility
| DPHARMA volatility | |
|---|---|
| DPHARMA Average Weekly Movement | 2.8% |
| Pharmaceuticals Industry Average Movement | 3.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in MY Market | 10.0% |
| 10% least volatile stocks in MY Market | 2.4% |
Stable Share Price: DPHARMA has not had significant price volatility in the past 3 months compared to the MY market.
Volatility Over Time: DPHARMA's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | n/a | Leonard bin Abdul Shatar | duopharmabiotech.com |
Duopharma Biotech Berhad, an investment holding company, researches, develops, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally. The company offers consumer healthcare products comprising vitamins and supplements, analgesics, eyecare, antacids, and skin care products; and generic drugs for various therapeutic classes, such as cardiovascular, dermatology, hormones, respiratory, sensory and nervous system, musculo-skeletal system, anti-infectives, and others. It also provides specialty pharmaceutical drugs for targeted conditions, biosimilar products, and medical devices and consumables to patients with conditions, such as diabetes, cancer, cardiovascular diseases, renal diseases, and others.
Duopharma Biotech Berhad Fundamentals Summary
| DPHARMA fundamental statistics | |
|---|---|
| Market cap | RM 1.19b |
| Earnings (TTM) | RM 56.06m |
| Revenue (TTM) | RM 787.53m |
21.1x
P/E Ratio1.5x
P/S RatioIs DPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DPHARMA income statement (TTM) | |
|---|---|
| Revenue | RM 787.53m |
| Cost of Revenue | RM 506.08m |
| Gross Profit | RM 281.44m |
| Other Expenses | RM 225.38m |
| Earnings | RM 56.06m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.058 |
| Gross Margin | 35.74% |
| Net Profit Margin | 7.12% |
| Debt/Equity Ratio | 75.4% |
How did DPHARMA perform over the long term?
See historical performance and comparisonDividends
2.3%
Current Dividend Yield48%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 13:51 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Duopharma Biotech Berhad is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hsien Jin Lam | CGS International |
| Kenneth Leong | Malacca Securities Sdn Bhd |
| Norfauzi Bin Nasron | OSK-DMG |